Algernon Pharmaceuticals A Aktie

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has finalized the acquisition of its NP-120 (Ifenprodil) research program by US-based Seyltx Inc in a deal valued at US$2 million in cash along with a 20% equity stake in Seyltx. Ifenprodil is a potential first-in-class treatment for chronic cough, targeting the NMDA receptor to suppress the urge to cough. » Mehr auf proactiveinvestors.com

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has said it is considering the potential spin-off of its NP-120 (Ifenprodil) chronic cough research program. The company said it has engaged Maxim Group LLC to provide financial advisory and investment banking services with a focus on identifying and evaluating potential mergers and acquisitions (M&A) and strategic opportunities including the potential spin-off. » Mehr auf proactiveinvestors.com

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (N,N-Dimethyltryptamine or DMT) to treat stroke and traumatic brain injury (TBI). The safety review committee confirmed that there were no safety or tolerability issues with the highest dose, which was able to maintain plasma DMT concentrations at targeted levels and which was below the established psychedelic dose. » Mehr auf proactiveinvestors.com